Group items tagged

The Health and Social Care Select Committee (HSCC) on Tuesday held the first session in their pharmacy inquiry, with a panel of experts discussing the key issues facing community pharmacies in the country. Representatives from community pharmacy associations highlighted some of their biggest challenges and their vision for the future, as well as actions that government and NHS England can take to address those challenges for a better future for the sector. Opening the session, the Committee's vice-chair, Rachel Maskell MP, asked the representatives if they felt the government was ambitious enough in what it believes community pharmacy can do to address NHS pressures, or are pharmacists being held back by issues around workforce funding, contracting, and technological changes. Malcolm Harrison, Chief Executive, Company Chemists' Association (CCA), expressed that the government is not ambitious enough, saying "there's always opportunity to be more ambitious".

Former superintendent pharmacist and National Pharmacy Association (NPA) director, Phil Galt, has been appointed the new UK managing director for pharmacy software supplier Cegedim Rx. The position was previously held by Adam Dennett, who resigned after a successful ten-year tenure to pursue a new career outside healthcare, the company said. Cegedim Rx, the pharmacy entity of Cegedim Healthcare Solutions UK, announced the new appointment this month (April 5). Tristan de Foucher, head of European operations for Cegedim Group, said: "Adam has been a force of nature in this business for the past 10 years. Under his leadership, the team has continuously and successfully invested in and driven product innovation to stay ahead of the ever-changing demands placed upon community pharmacy." Galt has over 20 years of experience as a qualified pharmacist and a successful business leader. He has worked extensively in community pharmacy, focusing on both care delivery and technology implementation.

Titan PMR, a pioneer of cutting pharmacy technology has set up additional new team of 12 staff to cater for a deluge of independent pharmacists investing in new businesses. The company is utilising the opportunity that is underway as large chains look to sell off or close their community pharmacies, offering an opportunity for pharmacists looking to provide efficient dispensing and additional services. In January this year Lloyds Pharmacy, which was bought by a private equity firm in 2022, announced plans to close all its 237 branches inside Sainsbury's stores over the course of 2023. Currently, more than 5,500 of around 14,000 registered pharmacy premises across the UK are owned by corporates and supermarkets. Titan PMR - an innovative, cloud-based system which manages end-to-end pharmacy workflow - has become the preferred software platform especially amongst first time buyers who are keen to offer new services to patients. The new team at the Bristol-based company, hired to support this sector, sees its total workforce growing to more than 50 staff.

Omnicell Limited, a wholly owned subsidiary of Omnicell - an American healthcare technology company, has signed an agreement with the shareholders of Hub and Spoke Innovations Limited to acquire Hub and Spoke Innovations. Hub and Spoke Innovations Limited is distributor of the Pharmaself24 prescription collection kiosk in Great Britain. The move will complement Omnicell's total solution technology portfolio for retail pharmacy in the UK, including a pack-pick dispensing robot, automated MDS filling machine and eMAR solution, thereby helping pharmacies to improve workflows and offer a 24/7 access to medications and patient care. It will also help community pharmacies achieve their goals, as they increasingly look at ways to make their businesses more efficient and free up staff to offer more pharmaceutical care and services to patients. In short, the deal would enable Omnicell to offer a wider range of digital technologies to streamline retail pharmacy operations, allowing pharmacists to spend more time with patients and focus on value-added, revenue-generating healthcare services, such as vaccinations.

American healthcare technology company Omnicell has appointed Edward Platt as the new Senior Commercial Director of its UK community pharmacy division. Along with this new role, Edward, who joined Omnicell in 2015, will continue his current leadership remit for Omnicell's UK & Ireland hospital division. He will be leading a revamped commercial team, which would be responsible for increasing Omnicell's footprint of automation and consumable solutions delivered into UK community pharmacies. As part of the revamp, the company has created dedicated specialist teams to ensure the needs and challenges of community pharmacists (small independents and small multiple operators) can be fully understood and supported.

The Royal Pharmaceutical Society (RPS) has awarded Professor Abdul Basit with the RPS Harrison Memorial Medal for an outstanding contribution to advancing pharmaceutical science. Professor Basit graduated with a First Class Honours degree in Pharmacy from the University of Bath, and received his PhD from The School of Pharmacy, University of London. Currently in position as Professor of Pharmaceutics at the UCL School of Pharmacy, he is internationally recognised for leading in the field of drug delivery, microbiome medicines, three-dimensional printing of pharmaceuticals and digital health. He has also founded three start-up companies. Professor Basit has an impressive track record of publications, and a lifetime grant and investment income of over £100million pounds. His research has led to a series of transformative drug delivery systems, translated into the design of new technologies and improved therapies, many of which have been commercialised and launched worldwide including a new treatment for inflammatory bowel disease. To date, more than a million patients have benefited from inventions created and developed in the Basit Research Group.

Ahead of the launch of UK's first state-of-the-art automated hub for independent community pharmacists, HubRx has announced the appointment of Karl Wooldridge as operations director and Matthew Tollefson as chief financial officer. Karl brings more than 14 years of sector experience to his new role with HubRx. Having begun his career as an independent community pharmacist, Karl has gone on to hold key roles within pharmacy automation, including managing Phoenix Medical Supplies' offsite dispensing service. Commenting on his appointment, Karl said: "I'm delighted to have joined the team. The pandemic has further highlighted the important role pharmacists can play in keeping the nation healthy, not least in the delivery of the latest vaccination programme. The focus is now on pharmacists offering more clinical services, but to be able to achieve that the dispensing burden needs to be reduced. "HubRx is pioneering, our approach will transform community pharmacy. We're investing in cutting-edge technology to create an automated dispensing hub that will create capacity for pharmacists, allow them to grow and expand their skills." Matthew joins from Leeds-based corporate finance firm, Sentio Partners having also held positions with Mazars and Ernst & Young.

Talk of hub and spoke models has been rumbling on for as long as I can remember. The topic has once again hit the headlines as the government announced a fresh consultation for its proposed changes, calling on all interested parties to submit their views by 8th June. The argument for hub and spoke is to allow independents to have the same level playing field as the larger groups who have been operating this model for some time. The government also sees significant efficiency gains in centralisation, arguing this will free pharmacists time away from dispensing to focus on clinical services. The latest consultation advocates two models being created. In the first model, the dispensed medication is sent back to the spoke. In the second model, the completed medication can be sent out directly to the patient. The latter is a new concept which could open up new opportunities in how services are delivered. Pharmacies could effectively outsource the entire dispensing and delivery to housebound patients and care homes allowing pharmacies to take on new business without having to worry about logistics and geography.

The Company Chemists' Association (CCA) has called for an evidence-based approach to hub and spoke dispensing proposals, stating that it is vital to back the changes based on robust data and lived experience of pharmacy businesses. Community pharmacy contractors need to to respond to a Department of Health and Social Care initiated consultation on the hub-and-spoke dispensing models by June 8. Malcolm Harrison, CEO of the CCA, said: "I am very concerned by both the number and scale of the assumptions contained within the impact assessment, which are unlikely to come to fruition. "The impact Assessment also makes predictions on a yet un-born market, stretching 10 years into the future. Hub and spoke technologies do have the potential to enable new dispensing models in the future if new commissioning can support a change in operations. I would caution against firm predictions about likely benefits without stronger commitments to enablers of change."

NHS Somerset is aiming to grow its referral rate through GP Community Pharmacist Consultation Service (GP CPCS) to between 4,000 to 6,000 patients a month. Since June 2021 GPs in Somerset have successfully referred around 1,000 patients a month through the Somerset GP Community Pharmacist Consultation Service (GP CPCS) Currently, 59 of NHS Somerset's 64 GP practices and all of Somerset's 102 community pharmacists are using the Somerset GP CPCS. NHS Somerset found that providing the right training for GPs and for reception staff and practice managers was key to a smooth rollout and uptake of the service. As was making sure the technology worked when making referrals from general practice to community pharmacists. NHS Somerset is using software called Patient Access Connect, which seamlessly integrates with the EMIS Web GP system used in Somerset, to give practices a quick and easy way to capture the patient information needed to deliver a referral.

Wales launched the new electronic prescribing service (EPS) last week, with the country's first electronic prescription sent and dispensed on 17 November. The new service allows prescriptions to be sent digitally to a patient's nominated pharmacy, thus eliminating the need for paper forms. It is part of a wider plan to introduce digital medicines and e-prescribing in all hospitals and primary care in the country. Wellington Road Pharmacy and Lakeside Medical Centre in Rhyl became the first community pharmacy and GP practice to use the EPS, which is expected to be rolled out across Wales in January 2024.

The life cycle management company, Pharmanovia, has appointed Nivedita Valentine as associate vice president of Product Innovation. Ms Valentine will oversee the company's product innovation operations and decision-making as Pharmanovia continues to focus efforts on both, identifying new prospects to enhance lifecycle management of its brands through incremental innovation. She will report to interim chief scientific officer Stephen Deacon and help bridge unmet patient needs with the help of novel therapies, originating both from in-house development and through partnerships. Ms Valentine currently holds positions on the value-added medicines committee within Medicines for Europe and the International Rare Diseases Research Consortium (IRDiRC) Task Force on Drug Repurposing Guidebook. Pharmanovia CEO Dr James Burt commented: "Digitalisation and utilising the latest technological innovation are notable areas of acceleration within the pharma industry and Nivedita's appointment will ensure iconic brands will continue to be improved, supported, and used sustainably.

The government on Wednesday (March 2) announced an investment of £260 million to support research, development and manufacturing of new drugs, devices and diagnostics. Of the total funding, up to £200m has been allocated for research to better access NHS data through Trusted Research Environments and digital clinical trial services, enabling availability of crucial data with the highest levels of privacy. This will allow the NHS to deliver new life-saving treatments to patients, tackle health inequalities and improve patient care, a government release stated. The remaining £60m will support commercial-scale manufacturing investments by companies at the leading-edge of innovation, from cell and gene therapies and earlier and better diagnostic technologies, to medical devices. The funding for manufacturing investments will be distributed through the new Life Sciences Innovative Manufacturing Fund (LSIMF), following the success of the earlier Medicines and Diagnostics Manufacturing Transformation Fund.

NHS England has secured a deal for 'Dexcom ONE Real Time-Continuous Glucose Monitoring' device which will help type 1 diabetes patients to keep track of their glucose levels at all times without having to scan or take a finger prick test. Once the patients receive their starter pack - which will include information on the product and usage, a sensor and transmitter - from the hospital or GP surgery, they can go to the community pharmacy for their repeat prescription. The wearable arm gadget sends information to a mobile app and allows diabetes patients to keep track of their glucose levels. "Traditionally, continuous glucose monitors are more expensive than their flash monitor counterparts - which record glucose levels by scanning a sensor - but thanks to the NHS agreeing on a new cost-effective deal with manufacturers DEXCOM, they will now be available for NHS patients on prescription at a similar price," said NHS. Dexcom ONE Real Time-Continuous Glucose Monitoring, uses a sensor no bigger than a bottle cap that attaches to the arm for up to 10 days and measures glucose levels from just under the skin. The wider rollout of the technology will help diabetes patients manage their condition better - reducing hospitalisations and associated diabetic illnesses which will ultimately ease pressure off the NHS. Karen Baxter, vice president, UK & Ireland, Benelux, France and Spain at Dexcom: "The addition of Dexcom ONE to the NHS England drug tariff is enormous progress towards improving the choice of diabetes tech, providing an alternative to burdensome finger pricks and scanning.

Titan PMR has been accredited by the NHS to provide electronic prescription services (EPS) to dispensing doctors. Over 1,000 of these doctors, who provide a vital service to almost 10 million people in rural communities, can now offer their patients the same level of benefits and efficiencies that electronic prescriptions and Titan PMR have brought to pharmacies around the UK. These features will also increase efficiency for dispensing doctors, who will reduce dispensing errors and improve organisation, increasing their capacity while enjoying the ability to integrate with other technologies. After a full year of testing, including six months of compliance testing at a practice in Cumbria, the new accreditation for Titan also has potential to help the NHS fulfil its target of all prescriptions being issued electronically. Currently written paper prescriptions from dispensing doctors account for around seven per cent of the total prescriptions in England - around 6.5 million each month. "Until now dispensing doctor surgeries have basically been in the digital dark ages when it comes to dispensing medicines," said Tariq Muhammad, a tech entrepreneur and CEO of Bristol-based Invatech Health, which developed Titan PMR.

In a rapidly evolving and competitive landscape, the pharmaceutical industry faces unique challenges when it comes to marketing its products and services. With stringent regulations, complex target audiences, and a need for trust and credibility, pharma companies need to employ effective marketing strategies to stand out in the crowd. In this blog article, we will explore some key marketing strategies for the pharma industry that can help boost their visibility, engage their target audience, and drive business growth. UNDERSTANDING THE UNIQUE LANDSCAPE The pharma industry operates in a highly regulated environment, where compliance and ethical considerations play a crucial role. Before diving into marketing strategies, it is essential to have a deep understanding of the industry's dynamics and the target audience. Researching the market, identifying patient needs, and studying the competitive landscape are vital steps in developing an effective marketing plan. EMBRACING DIGITAL TRANSFORMATION Digital transformation has revolutionized marketing across industries, and the pharma sector is no exception. Embracing digital channels and technologies can significantly enhance the reach and impact of marketing efforts. Pharma companies can leverage social media platforms, create engaging content, and build online communities to connect with patients, healthcare professionals, and other stakeholders. Implementing robust digital marketing strategies allows for personalized messaging, real-time communication, and targeted campaigns that resonate with the target audience.

Seven NHS trusts in England are set to begin trials of new wireless technologies to help improve patient care and strengthen connectivity in A&Es and ambulance bays. They have been awarded around £1 million as part of NHS England's Wireless Trials programme, which aims to leverage advanced wireless technologies to enhance patient care and experiences while freeing up more staff time. Manchester University NHS Foundation Trust will introduce an innovative approach of combining satellite and cloud-based wireless solutions to enhance connectivity across its 10 hospital sites and wider community services. At Mid Cheshire and Princess Alexandra Hospital NHS trusts, wireless trackers will be installed on medical equipment and hospital beds. This will allow real-time monitoring and location tracking, enabling easy accessibility for staff to locate necessary items promptly.

NHS England is rolling out a range of tech and data solutions, including an artificial intelligence (AI) system, across the health service to tackle winter pressures. The AI system will be used to identify patients at risk of hospital admission so community NHS teams can get to them first and reduce pressures on A&E departments. On a trial basis, four GP practices in Somerset have started using the innovative technology which can highlight registered patients with complex health needs. Health coaches, nurses, or GPs will then reach out to the people most at risk, and provide them with a range of preventive care such as monitoring, food parcels, cleaning, shopping, as well as escalating care to specialist doctors.

Ten-year volume and sales forecasts for 40 blood typing, grouping and infectious disease screening tests, including NAT procedures performed in US community and regional blood centers, hospitals, commercial laboratories, and plasma fractionation facilities.